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ABSTRACT 
Sera from patients with ovarian cancer contain autoantibodies (AAb) to tumor-derived proteins that are 
potential biomarkers for early detection. To detect AAb, we probed high-density programmable protein 
microarrays (NAPPA) expressing 5,177 candidate tumor antigens with sera from patients with serous ovarian 
cancer (n=34 cases/30 controls) and measured bound IgG.  Of these, 741 antigens were selected and probed 
with an independent set of ovarian cancer sera (n=58 cases/60 controls). Twelve potential autoantigens were 
identified with sensitivities ranging from 13-22% at >93% specificity.  These were retested using a Luminex 
bead arrays using 60 cases and 60 controls, with sensitivities ranging from 0-31.7% at 95% specificity. Three 
AAb (p53, PTPRA, and PTGFR) had area under the curve (AUC) levels>60% (p<0.01), with the partial AUC 
(SPAUC) over 5 times greater than for a non-discriminating test (p<0.01). Using a panel of the top three AAb 
(p53, PTPRA, and PTGFR), if at least two AAb were positive, the sensitivity was 23.3% at 98.3% specificity. 
AAb to at least one of these top three antigens were also detected in 7/20 sera (35%) of patients with low 
CA125 levels and 0/15 controls. AAb to p53, PTPRA, and PTGFR are potential biomarkers for the early 
detection of ovarian cancer.  
INTRODUCTION 
Ovarian cancer is the fifth leading cause of cancer-related mortality of women in the U.S., with over 
15,000 deaths per year 
1
.  Early diagnosis is associated with improved overall survival 
2
; however, the majority 
of patients are currently diagnosed with advanced disease.  The five-year survival rate for late-stage ovarian 
cancer remains less than 30%.  Despite the identification of serum CA 125 as a biomarker for ovarian cancer in 
1983 
3
, there are currently no screening biomarkers recommended for use for the general population. 
The utility of CA 125 as a screening test is limited by a low sensitivity of 50% for early stage disease at 
99% specificity 
4
.  Combining CA 125 with transvaginal ultrasound (TVUS) increased the specificity of 
detection in the UKCTOCS large-scale screening trial 
5
.  In a joint validation study of 28 potential markers for 
detecting ovarian cancer in blood 
6
, the most accurate marker remains CA 125, followed closely by HE4 
7
.   
Panels of markers demonstrated only marginal improvements over CA 125 alone for the early detection of 
disease.  A recent study showed that the addition of CEA and VCAM-1 to CA 125 and HE4 increased the 
sensitivity of detection of stage I and II ovarian cancer to 86% at 98% specificity 
8
, but this remains to be 
confirmed in a blinded validation study using prediagnostic sera. Biomarkers are needed that complement CA 
125 and HE4. 
Protein overexpression or mutation can lead to the spontaneous development of autoantibodies (AAb) in 
the sera of patients with cancer 
9
.  Tumor antigen-specific AAb have been identified in the sera of patients with 
cancer, including patients with early-stage disease 
10
.  There are several potential advantages of AAb 
biomarkers, including signal amplification by the immune response and persistence of antibodies after antigen 
is no longer detected.   P53-specific AAb, which are associated with p53 mutation and resultant protein 
stabilization, have been detected in early-stage ovarian cancer 
11
.  We detected p53-specific AAb in 41.7% of 
patients with serous ovarian cancer at 91.7% specificity 
12
.  Unlike CA 125 and HE4, p53-AAb were associated 
with improved survival [HR=0.56] 
12
.     
We hypothesized that the identification of novel AAb biomarkers beyond p53-AAb would increase the 
sensitivity of detection of serous ovarian cancer.  We used the custom protein microarray technology Nucleic 
Acid Protein Programmable Arrays (NAPPA), which are generated by printing full-length cDNAs encoding the 
target proteins at each feature of the array.  The proteins are then transcribed and translated by a cell-free system 
and immobilized in situ using epitope tags fused to the proteins 
13
.  Sera are added, and bound IgG is detected 
by standard secondary reagents.  NAPPA arrays have been used to identify antibody signatures in early-stage 
breast cancer 
10d, 14
. 
The objective of this study was to identify novel AAb biomarkers for the detection of serous ovarian 
cancer.  To profile the ovarian cancer immune response, we developed protein microarrays displaying 5,177 
full-length candidate antigens. We used a sequential screening strategy to select candidate AAb biomarkers to 
limit the false discovery rate inherent to large-scale proteomic screening.  First, we screened 34 cases of serous 
ovarian cancer and 30 matched healthy controls (Cohort 1) on all 5,177 candidate tumor antigens, and selected 
741 antigens for further testing.  Second, we screened 60 cases and 60 healthy controls (Cohort 2) on the 741 
antigens, and identified 12 potential candidate AAb biomarkers. Third, we used an independent assay (Luminex 
bead array) to display these autoantigens, and re-screened sera from women in Cohort 2.  Finally, we displayed 
a smaller set of 7 autoantigens and screened sera from an independent set (Cohort 3) of non-serous cancers 
(n=30), false-negative CA 125 (n=20), benign ovarian disease (n=30), and healthy controls (n=30).  The 
sensitivity and specificity of each individual biomarker, as well as the biomarker panel, is presented.  
  
METHODS 
Patient Sera 
Sera used in these analyses were obtained from the Brigham and Women’s Hospital and the Dana-Farber 
Cancer Institute with support from the NCI Early Detection Research Network and Ovarian SPORE program.  
Sera derived from ovarian cancer patients were obtained at the time of presentation prior to surgery, and 
patients received routine post-operative therapy (as described in 
12
).  One case in Cohort 1 was obtained 
postoperatively. The non-serous cases were derived from 10 patients with endometrioid cancer, 10 patients with 
clear cell carcinoma, and 10 patients with mucinous carcinoma.   The benign disease samples were derived from 
19 patients with serous cytadenomas and 11 patients with mucinous cystadenomas. Sera from age-matched 
general population control women were obtained from the Brigham and Women’s Hospital using a standardized 
serum collection protocol and stored at -80
o
C until use. Cases and matched controls were processed 
simultaneously. Women with a personal history of cancer (other than non-melanoma skin cancer) were 
excluded as controls.  Written consent was obtained from all subjects under institutional review board approval.  
For the serous cases included in the survival analysis, medical records were reviewed and details related to 
presentation and treatment abstracted. 
 
Plasmid repository and high-throughput DNA preparation 
Sequence-verified, full-length cDNA expression plasmids in flexible donor vector systems were obtained from 
the Arizona Biodesign Institute and are publicly available (www.dnasu.edu).  These were converted to the T7-
based mammalian expression vector pANT7_GST using LR recombinase (Invitrogen, Carlsbad, CA). The high-
throughput preparation of high-quality supercoiled DNA for cell-free protein expression was performed as 
described 
15
. For bead array ELISAs, larger quantities of DNA were prepared using standard Nucleobond 
preparation methods (Macherey-Nagel Inc., Bethlehem, PA).  All 12 selected genes were sequence-confirmed 
prior to validation studies. 
 
Detecting serum antibodies on NAPPA arrays 
Detection of serum Abs on NAPPA arrays was performed as described 
16
.  Plasmid DNA (1.5 g/mL), capture 
antibody (50 g/mL anti-GST antibody, GE Healthcare Biosciences, Piscataway, NJ) or anti-FLAG antibody 
(Sigma-Aldrich, St. Louis, MO), protein crosslinker (2 mM, BS3, Pierce, Rockford, IL) and BSA (3 mg/mL, 
Sigma-Aldrich) were co-printed onto the array surface.  All samples were printed using a Genetix QArray2 with 
300 m solid tungsten pins on amine-treated glass slides.  The printed DNA was transcribed and translated in 
situ using reticulocyte lysate according to previously published protocols 
14
.  Protein expression was detected 
using anti-GST MAb (Cell Signaling, Danvers, MA) diluted at 1:200.  For detecting serum antibodies, the 
arrays were incubated with serum diluted 1:250-1:600 in 5% PBS milk with 0.2% Tween 20 overnight and 
detected with anti-human IgG-HRP (Jackson ImmunoResearch Labs, West Grove, PA) with Tyramide 
(PerkinElmer, Waltham, MA). Slides were scanned with a Perkin Elmer ProScanArray HT. The highly 
immunogenic EBV-derived antigen, EBNA-1, was included as N- and C-terminal fragments for positive control 
antigens.  Negative controls included empty vectors and no DNA controls.  Registration spots for array 
alignment were printed with purified human IgG proteins.  
 
Detection of antibodies on Luminex bead arrays.  
In vitro expression and display of target protein antigens on Luminex bead arrays was described in 
17
.  Briefly, 
each target gene was expressed as a C-terminal GST-fusion protein using T7 reticulocyte lysate (Promega 
Corporation, Madison, WI) per manufacturer’s recommendations with 500 ng DNA.  Vector and p21-GST were 
also expressed as negative controls.  The in vitro transcription/translation (IVTT) products were each captured 
onto SeroMAP carboxylated microspheres (Luminex Corporation, Austin, TX) coupled with anti-GST antisera.   
Protein-bound microspheres were pooled together and blocked with 10% each of normal sera from mouse, 
rabbit, goat, and rat (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA), 0.5% polyvinyl alcohol 
(PVA, Sigma-Aldrich, St. Louis, MO), 0.8% polyvinylpyrrolidone (PVP, Sigma-Aldrich, St. Louis, MO), and 
2.5% Chemicon (Millipore, Billerica, MA) in PBS-1% BSA.  Test sera were diluted 1:80 in blocking buffer, 
pre-incubated at room temperature for 1 hr with rotation, and then incubated with the beads overnight at 4C 
while shaking. Bound IgG was detected with biotin-conjugated goat anti-human IgG antibody (Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA) and streptavidin-R-PE (Molecular Probes, Inc., Eugene, 
OR). To control for non-specific and GST-specific autoantibody background, the ratio of MFI for individual 
Abs to the MFI for the control p21-GST antigen was determined.  Protein expression was confirmed with a 
mouse anti-GST monoclonal Ab (Cell Signaling Technology, Danvers, MA) and PE-conjugated goat anti-
mouse IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).  
 
Detection of CA 125, and HE4 in sera 
The detection of CA 125 and HE4 in these sera has been reported 
12
.  CA 125 was detected by immunoassay 
using two monoclonal antibodies [M 11 and OC 125, Fujirebio Diagnostics].  The upper 95
th
 percentile cutoff 
for healthy pre- and post-menopausal women is 35 U/mL. [HE4] was detected using a double monoclonal 
ELISA (RK®, Fujirebio Diagnostics).   
 
Statistical Analysis 
For the pre-screen, 34 cases and 30 control sera (Test set, Cohort 1) were screened on 5,177 antigens displayed 
in NAPPA protein array format. Each array was normalized by first removing the background signal estimated 
by the first quartile of the non-spots and then log-transforming the median-scaled raw intensities to bring the 
data to the same scale and stabilize the variance across the range of signals.  Candidate antigens from the initial 
5,177 antigens were selected if they met two different criteria: 1) comparison of the 95
th
 percentiles of the cases 
and controls using quantile regression 
18
 and 2) comparison of the proportion of cases with intensities above the 
95
th
 percentile of controls to the expected number seen by chance using binomial tests, with a p-value<0.05. 
Independent arrays of these 741 candidate antigens were screened with a fully independent set of age-
matched sera consisting of 60 healthy controls and 60 patient sera.  We normalized these arrays as follows.  
First, we removed any duplicate antigen pairs that differed by more than 3 times the median absolute deviation, 
resulting in removal of 0.2% of spots.  Second, we removed background signal by subtracting the first quartile 
of control spot (no DNA) intensity.  Third, to normalize across arrays and 384-well plates we divided the excess 
intensity by the median excess intensity for each array and 384-well plate. Two case sera failed our QC 
measures (more than 20% of spots below background signal) and were excluded from further analysis.  
We computed the sensitivity at an approximate 95% specificity for each antigen as follows.  We 
determined a threshold by computing the 95% empirical percentile of the normalized intensity values of the 
controls.  We then computed the sensitivity as the proportion of the cases that exceeded that threshold, and the 
actual specificity as the proportion of the controls that did not exceed the threshold. 
To identify the most sensitive antigens at a high level of specificity, we used receiver operator 
characteristic (ROC) curve analysis.  Specifically, we tested the hypothesis that the partial area under the ROC 
curve (PAUC) in the region where the specificity > 95% exceeds 0.00125, which is the PAUC for a non-
informative diagnostic test. P-values were computed using a normal approximation to the bootstrap sampling 
distribution and q-values were computed using the qvalue package in R
19
.  We used the training set to identify 
13 potential antigen biomarkers with q-values < 0.15 (i.e. significant with 15% false discovery rate control).  
Each of these antigens had a p-value < 0.01; for technical reasons 12 were used for further analysis.  
RAPID Luminex ELISA analyses were performed in duplicate.  Differences between cases and controls 
were assessed by chi-square tests.  To assess the added value of AAb along with CA 125 and HE4 to 
discriminate cases from healthy controls, we constructed ROC curves and calculated areas under the curve.  
Associations between clinical characteristics and AAb detection among cases were tested using logistic 
regression adjusted for age and Jewish ethnicity.  All p-values were two-sided.  Statistical analyses were 
performed using SPSS 14.0 software (SPSS Inc, Chicago, IL) and SAS (SAS Institute Inc., Cary, NC). 
  
RESULTS 
Strategy for Biomarker Selection 
Our primary goal was to identify serum AAb biomarkers that would distinguish serous ovarian cancer from 
healthy controls in order to guide further imaging and monitoring decisions. In order to identify a biomarker 
panel of AAb in ovarian cancer from 5,177 candidate antigens, sera were tested in sequential stages as 
described in Figure 1. All training and validation case and control sera were gender- and age-matched, 
collected prior to surgery (for cases), and under standardized collection protocols. Control sera and 
questionnaires were collected from healthy women in the Boston area with no history of cancer.  The serous 
cases were primarily stage III/IV (95%).  Table 1 shows the age distribution, menopausal status, and sample 
collection details of the cases and controls selected for these studies.  Cases and controls did not differ in age, 
race, menopausal status, year of blood collection, or length of storage.  Only the non-serous cases had a higher 
frequency of oral contraceptive (OC) use (p=0.003) compared to their matched controls.  As expected, they also 
had lower mean CA 125 levels (85 U/ml) compared to serous cases.  
 
In stage 1 of the biomarker selection, 5,177 antigens were pre-screened with sera (Cohort 1) from 34 cases of 
serous ovarian cancer and 30 matched controls. For stage 2, 741 selected antigens were screened with sera from 
60 cases and 60 matched controls (Cohort 2).  Twelve selected antigens were displayed on bead arrays, re-
screened with the training set to establish the performance of the assay.  Finally, 7 promising antigens were 
screened by bead arrays using non-serous cases (n=30) and healthy controls (n=30), as well as sera with low CA 
125 levels (n=20) and healthy matched controls (n=15). The clinical characteristics of the serous cases in the 
test, training, and validation sets were similar, but with lower CA 125 levels (mean=647), on average, in the 
validation set than in the test set (mean=1232). 
 
Generation of NAPPA Custom Protein Microarrays for Biomarker Detection 
High-density NAPPA protein microarrays were generated for these studies for biomarker detection as described 
14a
.  The 5,177 individual cDNAs used on these arrays were derived from the Arizona Biodesign Institute DNA 
repository.  These cDNAs were all sequence-verified, full length, wild-type genes fused in frame with either a 
C-terminal GST tag or N-terminal FLAG tag in a vector optimized for mammalian protein expression.   The 
content of these arrays have been described 
16
 and include the Breast Cancer 1000 gene set 
20
, selected for their 
association with breast cancer using bioinformatics and data mining tools.  Additional genes included over 300 
G-coupled protein receptors (GPCRs), 500 kinases, and 700 transcription factors. The cDNAs were coprinted 
on glass slides with anti-tag antibodies at a high density (up to 2300 antigens/slide; 3 slides/gene set). Proteins 
were expressed and captured in situ on the arrays using a coupled in vitro transcription-translation system 
derived from rabbit reticulocyte lysate. DNA content was confirmed by picogreen, and protein expression was 
confirmed by probing the arrays with anti-GST antibodies (not shown).  
 
Selection of the Antibody Biomarker Panel 
The goal for Stage 1 was to limit the number of screened antigens by eliminating all of the 
uninformative antigens (e.g., no difference between case and control).  This has the advantages of reducing the 
false positive rate and the cost of the screen.  Thus, 34 cases/30 control sera were screened with sera at 1:250 to 
1:600 dilution on 5,177 single antigens, and the arrays were normalized for background intensity (see Statistical 
Analysis). Protein expression of individual spots on the microarrays was confirmed with anti-GST (not shown), 
since the spotted cDNAs encode C-terminal GST fusion proteins.  The sera were added to the arrays, and bound 
IgG detected with secondary antibodies. The top 741 antigens (Supplemental Table 1) were selected if the 95
th
 
percentile of signal of cases and controls were significantly different (p<0.05) and if the number of cases with 
signals above the 95
th
 percentile of controls was larger than the number expected due to random chance 
(p<0.05).   
The goal of the second stage was to identify candidate AAb for further validation.  The selected 741 
cDNAs were printed in duplicate on single arrays. These arrays were screened with a separate training set of 
sera from serous ovarian cancer (n=58) and sera from healthy controls (n=60).  Two additional patient sera were 
removed from analysis due to unusually elevated background on the arrays (>5x mean).  From these data, 12 
antigens were selected as potential biomarkers for further analysis based upon a statistical test of the partial area 
under the receiver operator characteristic curve (see Statistical Analysis).  The selected antigens had p < 0.01 
and were significant with a <15% false discovery rate (FDR). 
 
Development of a high-throughput Luminex bead array ELISA for AAb detection 
For high-throughput screening of larger numbers of sera, the 12-antigen panel was displayed on a custom 
Luminex microbead array, which allows for rapid, multiplexed screening of sera in a readily exportable, pre-
clinical format. First, the performance characteristics of the 12 target antigens were evaluated using the same set 
of sera (Cohort 2) used to screen the 741 antigens (n=60 cases/60 controls, Table 2).   The sensitivities for these 
antigens are shown, using a cutoff that achieves 95% specificity.   AUC and scaled partial AUC (SPAUC) 
values and their respective p-values are also shown.  Overall, these data show that the sensitivity of each 
individual antigen is low (ranging from 0-31.7%), with AUC levels >60% for p53, PTGFR, PTPRA (p<0.01).   
Further, for these three antigens the partial area under the ROC curve is more than 5 times greater than for a 
non-discriminating test (SPAUC > 5; p < 0.01). 
 
Detection of autoantibodies in non-serous ovarian cancer  
To determine the performance characteristics of the biomarker panel for non-serous ovarian cancer, the 
Luminex bead array ELISA was used to determine AAb levels in cases derived from 10 patients with 
endometrioid cancer, 10 patients with clear cell carcinoma, and 10 patients with mucinous carcinoma (Table 3).   
For this analysis, the top 3 potential antigens (p53, PTGFR, and PTPRA) were selected, as well as 4 additional 
potential antigens from the validation assay.  As expected, p53 AAb were also detected in non-serous ovarian 
cancer, but at a lower AUC (57.4%), consistent with the lower frequency of p53 mutations (which are strongly 
associated with AAb formation) in these tumors 
21
.  In contrast, AAb to PTGFR and PTPRA were not detected 
in non-serous ovarian cancers.  Data on major risk factors for ovarian cancer (parity, ovulatory cycles, 
breastfeeding) as well as levels of the biomarker, CA15.3, was available on a limited number of subjects in this 
study.  No notable correlations were observed between the markers in Tables 2 and 3 and the epidemiologic 
factors (data not shown). 
 Detection of autoantibodies in the setting of low CA 125 
In the training and validation cohorts, CA 125 is elevated in over 95% of cases, due to selection of patients with 
serous carcinomas undergoing surgery.  To determine if the AAb panel has potential additive benefit beyond 
CA 125 for the detection of serous carcinomas, 20 sera were identified from patients with serous carcinoma 
who had low CA 125 levels (median 40, range 15-76.7).  These cases were matched by age and stage with 15 
sera with high CA 125 levels (median 2116, range 718-23,010) 
21
.  AAb to at least one of the top 3 antigens 
(p53, PTGFR, and PTPRA) were detected in 7/20 sera (35%) in the low CA 125 cohort (6 by p53 alone and 1 
by both PTGFR and PTPRA) and no controls using cutoff values of mean + 3 SD of the controls.  Of the 7 sera 
with AAb in the low CA 125 cohort, 2 had stage I/II and 5 had late stage III/IV serous carcinoma, with a 
median CA 125 level median of 39 (range 19-62). 
 
Detection of autoantibodies in the setting of benign ovarian disease 
One challenge with the CA 125 biomarker as a screening tool is false elevation in the setting of benign ovarian 
disease.  We evaluated the individual performances of p53, PTGFR, and PTPRA AAb in a separate set of sera 
from 30 serous ovarian cancer patients and 30 age- and gender-matched women with benign ovarian disease (19 
patients with serous cytadenomas and 11 patients with mucinous cystadenomas) 
21
. The sensitivity of detection 
of AAb to p53 in cases was 53.3% (AUC 0.86) at 93.3% specificity.  The sensitivity of PTGFR was 16.7% 
(AUC=0.57) and PTPRA was 13.3% (AUC 0.61) at 93.3% specificity.  
 
Multiplexed Analysis of the Three-Antigen Biomarker Panel 
We examined the utility of these 3 AAb biomarkers as a diagnostic panel from the combined training and 
validation sets.  27 out of 60 cases (45% sensitivity) scored high (95% specificity threshold for each antigen) on 
at least one of the 3 antigens, compared to only 8 out of the 60 controls (86.7% specificity).  However, due to 
the rarity of ovarian cancer in the general population and the clinical consequences of a false-positive result, the 
target specificity of biomarkers for ovarian cancer is 95%-99%.  At 95% specificity, the individual sensitivities 
of AAb to p53 was 21.7% (AUC=0.6475), PTGFR was 21.7% (AUC=0.6522), and PTPRA was 31.7% 
(AUC=0.6525). If at least two AAb of the three were positive above the 95% specificity cutoffs, the sensitivity 
was 23.3% with an improvement in overall specificity at 98.3%. 
 
  
DISCUSSION 
Using custom protein microarrays, we have identified a panel of 12 AAb biomarkers that were detected in the 
sera of serous ovarian cancer patients at the time of clinical diagnosis of invasive cancer, but not in healthy 
women.  These individual biomarkers had sensitivities ranging from 13-22% with specificities > 93%. Three of 
these biomarkers, p53, PTGFR and PTPRA, were consistently selective for serous ovarian cancer with 
individual AUCs ranging from 64.8-73.8% across two independent serum screenings and two technologic 
platforms (slide microarrays and bead arrays), involving a total of 94 cases/90 control samples. If at least two 
AAb of the three were positive, the sensitivity was 23.3% at 98.3% specificity. While the clinical sensitivity is 
modest, the reproducibility, signal intensity, and clinical specificity across multiple sample sets may provide 
utility beyond the biomarkers CA 125 and HE4. These biomarkers maintain sensitivity in the setting of false-
negative CA 125 levels, and, unlike CA 125, maintain specificity when compared to benign ovarian disease. 
This study is the first demonstration of the use of programmable protein microarrays for the proteomic 
detection of novel AAb biomarkers for ovarian cancer.  Almost all of the sera used for this study were from 
patients with stage III/IV ovarian cancer; evaluation of the performance characteristics of these biomarkers will 
require testing of pre-diagnostic, prospectively-collected cohorts such as the ROCA or PLCO trials.  It is 
reassuring that of the 5,177 antigens we screened, one of the top 12 AAb biomarkers was the well-established 
p53-AAb 
12
.  None of the 12 AAbs were detected in a similar screen for primarily ER+ breast cancer AAb 
16
, 
although p53-AAb have been detected in ER-breast cancers which are more commonly mutated in TP53 
14b
.  
The top antigen biomarkers did not correlate with known epidemiologic risk factors, such as parity, 
breastfeeding, or ovulatory years. Many of the top 12 antigen biomarkers we identified have also been described 
as important in ovarian cancer tumor biology and pathogenesis (Table 4).   
In addition to p53, which we had previously described, we consistently identified two novel ovarian 
autoantigens, PTGFR and PTPRA.  PTGFR (FP) is the cell surface prostaglandin F receptor that functions to 
initiate luteolysis in the corpus luteum. It is aberrantly expressed in endometrial carcinoma 
22
 and stimulation of 
the receptor triggers MAPK signaling and cell proliferation 
23
.  PTGFR is strongly expressed in murine ovarian 
follicles 
24
 as well as LNCaP prostate cancer cells upon disease progression 
25
.  PTPRA is a cell surface protein 
tyrosine phosphatase that is overexpressed in gastric cancers 
26
 and prostate cancers 
27
 and mediates signaling 
through ERK2. PTPRA is also upregulated in the setting of Her2 inhibition in breast cancer cell lines 
28
.     
Of the other candidate AAb biomarkers, validation testing using our bead-array ELISA and independent 
sera sets failed to confirm significant selectivity of the biomarkers.  This may reflect poor overall performance 
characteristics of these  biomarkers, or decreased sensitivity of the bead arrays for the detection of AAb 
compared to slide-based microarrays 
17
.   Many of these potential biomarkers are also associated with cancer 
pathogenesis. Dihydrofolate reductase (DHFR) is a folate metabolism enzyme and is critical for DNA 
biosynthesis. DHFR has long been a target for chemotherapy in multiple cancers 
29
, and gene amplification has 
been described in ovarian cancer 
30
.  In our data, DHFR AAb were more frequent in non-serous ovarian cancers. 
PSMC1 is an ATPase subunit of the 26S proteosomal complex. RAB7L1 is a member of the RAS oncogene 
family. Elevated serum prolactin (PRL) has been identified in the serum of ovarian cancer patients 
31
.  
CSNK1A1L is a kinase involved in the Wnt signaling pathway. AAb to PSMC1 have been identified in MGUS 
32
.  
 Many proteomics-based technologies have been used for the detection of antigen-specific antibodies in 
ovarian cancer (reviewed in 
33
). The Snyder laboratory used serum screening of spotted protein microarrays to 
identify 94 autoantigens.  Although the difference in detection between cases and controls did not reach 
statistical significance, they found Lamin A and RALBP1 were overexpressed in ovarian cancer tissue 
10a
.  
LC/MS-based approaches can identify native epitopes and post-translationally modified antigens; in one study 
100 AAb were identified in at least one patient 
34
.   Reverse-phase protein microarray 
35
 can identify PTM-
specific Abs, and the S100A7 antigen has been identified 
10c
.   Phage-displayed antigen microarrays have been 
used to identify 62 different antigens, including RCAS1, Nibrin, and RPL4 
10b
.  Finally, O-glycopeptide 
epitopes have been identified within MUC1 using glycoprofiling ELISA assays 
36
.   
 Additional proteomic methods have been used to identify ovarian cancer autoantigens. Using ascites 
fluid and protoarrays, 15 candidate AAb’s were identified 37.  Using commercial protein arrays, 202 candidate 
ovarian antigens were identified 
38
, with DHFR identified in at least one patient 
39
.  Using 2-D immunoblots of 
exosomes, ovarian cancer antigens PLAP, survivin, NY-ESO-1, GRP78, and CA 125 were identified 
40
.  Of the 
other 15 AAbs we identified, only casein kinase 1 A has similarity to a previously identified autoantigen, CK1-
epsilon 
41
.  In multiplexed analysis of select antigens (survivin, p53, p16, and cyclins B1, D1, A and E) AAb’s 
had a sensitivity of 62.5% at 90.2% specificity 
42
.  To our knowledge, other than p53, AAbs to these antigens 
have not been identified in ovarian cancer.  In summary, these studies identify a potential panel of three 
autoantibody biomarkers for the early detection of serous ovarian cancer using custom protein microarrays 
populated with cancer-related target antigens.   
 
Supporting Information 
This material is available free of charge via http://pubs.acs.org. 
Supplemental Table 1: List of the top 741 potential ovarian autoantigens, with normalized serum signal 
intensity for 60 cases and 60 controls. 
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 Table 1.  Characteristics of cases and controls 
 
 Cohort 1 Cohort 2  Non-Serous Set (Cohort 3) 
 Controls 
 
 
(n=30) 
n  (%) 
Serous 
cases 
 
(n=34) 
n  (%) 
 
Fisher’s 
exact 
p-value 
Controls 
 
 
(n=60) 
n  (%) 
Serous 
cases 
 
(n=60) 
n  (%) 
 
Fisher’s 
exact 
p-value 
Controls 
 
 
(n=30) 
n  (%) 
Non-
Serous
†
 
cases 
(n=30) 
n  (%) 
 
Fisher’s 
exact 
p-value 
          
Age           
  <50 1 (3.3) 2 (5.9) 0.89 18 (30.0) 17 (28.3) 0.99 16 (53.3) 16 (53.3) 0.99 
  50-60 10 (33.3) 11 (32.4)  23 (38.3) 23 (38.3)  9 (30.0) 9 (30.0)  
  >60 19 (63.3) 21 (61.8)  19 (31.7) 20 (33.3)  5 (16.7) 5 (16.7)  
Menopausal status          
  Pre  3 (10.0) 3 (8.8) 0.87 20 (33.3) 16 (26.7) 0.55 17 (56.7) 14 (48.3) 0.60 
  Post  27 (90.0) 31 (91.2)  40 (66.7) 44 (73.3)  13 (43.3) 15 (51.7)  
Race          
  White 28 (93.3) 32 (97.0) 0.50 60 (100.0) 53 (94.6) 0.11 30 (100.0) 26 (86.7) 0.11 
  Non-white 2 (6.7) 1 (3.0)  0 (0.0) 3 (5.4)  0 (0.0) 4 (13.3)  
OC use          
  Never 17 (56.7) 20 (60.6) 0.75 20 (33.3) 23 (41.1) 0.44 6 (20.0) 18 (60.0) 0.003 
  Ever 13 (43.3) 13 (39.4)  40 (66.7) 33 (58.9)  24 (80.0) 12 (40.0)  
Parity          
  Nulliparous 3 (10.0) 3 (8.8) 0.87 9 (15.0) 13 (23.6) 0.34 6 (20.0) 15 (50.0) 0.03 
  Parous 27 (90.0) 31 (91.2)  51 (85.0) 42 (76.4)  24 (80.0) 15 (50.0)  
Year of specimen 
collection 
         
  2001-2002 9 (30.0) 11 (32.4) 0.85 18 (30.0) 11 (18.3) 0.36 8 (26.7) 8 (26.7) 0.99 
  2003-2005 14 (46.7) 17 (50.0)  21 (35.0) 25 (41.7)  13 (43.3) 14 (46.7)  
  2006-2010 7 (23.3) 6 (17.6)  21 (35.0) 24 (40.0)  9 (30.0) 8 (26.7)  
Length of storage          
  <5.4 years 7 (23.3) 8 (23.5) 0.92 24 (40.0) 26 (43.3) 0.10 10 (33.3) 9 (30.0) 0.99 
  5.4-7.6 years 11 (36.7) 14 (41.2)  13 (21.7) 21 (35.0)  10 (33.3) 11 (36.7)  
  >7.6 years 12 (40.0) 12 (35.3)  23 (38.3) 13 (21.7)  10 (33.3) 10 (33.3)  
CA 125          
  Mean (95% CI)  1044 (550, 1984)  647 (434, 966)  85 (50, 145) 
          
* Includes two cases which were excluded from the NAPPA analysis due to background. 
† 
Non-serous cases are 10 mucinous, 10 endometrioid and 10 clear cell cases. 
 
Table 2. Statistics for 12 Potential Ovarian Cancer Biomarkers 
Protein Sens Spec Cutoff AUC 
AUC 
p-value SPAUC 
SPAUC 
p-value 
ACSBG1 13.3% 95.0% 2.07 53.9% 0.2287 1.11 0.4351 
AFP 15.0% 95.0% 1.41 54.4% 0.1971 3.56 0.0516 
CSNK1A1L 10.0% 95.0% 2.27 52.9% 0.2819 1.56 0.2956 
DHFR 13.3% 95.0% 1.49 52.0% 0.3722 3.78 0.0392 
MBNL1 0.0% 95.0% 4.96 50.0% 0.5076 0.00 1.0000 
p53* 21.7% 95.0% 9.34 64.8% 0.0024 5.56 0.0054 
PRL 10.0% 95.0% 1.29 53.9% 0.2122 3.11 0.0866 
PSMC1 10.0% 95.0% 1.71 51.6% 0.3743 2.89 0.0962 
PTGFR* 21.7% 95.0% 1.71 65.2% 0.0019 8.00 0.0002 
PTPRA* 31.7% 95.0% 1.59 65.2% 0.0019 7.11 0.0007 
RAB7L1 11.7% 95.0% 1.96 53.9% 0.2554 3.11 0.0780 
SCYL3 8.3% 95.0% 3.91 53.4% 0.2735 2.67 0.1293 
 
 
Table 3. Evaluation of 7 Potential Ovarian Cancer Biomarkers for Non-Serous Ovarian Cancers 
Protein Sens Spec Cutoff AUC 
AUC 
p-value SPAUC 
SPAUC 
p-value 
DHFR 16.7% 93.3% 3.02 58.7% 0.1311 5.78 0.0426 
p53 20.0% 93.3% 2.42 57.4% 0.1931 7.11 0.0203 
PSMC1 6.7% 93.3% 2.78 46.1% 0.6612 1.78 0.4179 
PTGFR 10.0% 93.3% 1.99 51.4% 0.4127 1.78 0.3996 
PTPRA 20.0% 93.3% 1.92 51.0% 0.4631 2.67 0.1998 
RAB7L1 10.0% 93.3% 1.80 46.0% 0.7204 1.33 0.4548 
SCYL3 6.7% 93.3% 7.01 50.2% 0.5234 2.67 0.2815 
 
  
 Table 4. Cellular functions of 12 candidate biomarkers 
Gene   Description   
Subcellular 
Location 
  General Function   Cancer-related Function 
ACSBG1   
acyl-CoA synthetase 
bubblegum family 
member 1 
  
cytoplasm, 
ER 
  
fatty acids metabolism and 
myelinogenesis 
    
AFP   alpha-fetoprotein   extracellular   
a major plasma protein produced 
by the yolk sac and the liver 
during fetal life 
  
- certain ovarian tumors with an elevated 
level of AFP were extremely reponsive to 
chemotherapy (PMID:19225928) 
                - serological marker for liver cancer 
CSNK1A1L   
casein kinase 1, alpha 
1-like 
  cytoplasm         
DHFR   
dihydrofolate 
reductase 
      
converts dihydrofolate into 
tetrahydrofolate 
    
MBNL1   
muscleblind-like 
(Drosophila) 
  cytoplasm   RNA processing     
 
  
 
  
 
  
 
    
P53   tumor protein p53   nucleus   tumor suppressor   
autoantibodies found frequently in serous 
ovarian cancer (PMID:20200435) 
PRL 
 
prolactin 
 
extracellular 
 
peptide hormone/cytokine that 
regulates development of 
mammary tissue, lactation, 
pregnancy 
 
- serum marker for ovarian cancer 
(PMID:15890779, 18258665) 
                
- inhibits apoptosis of ovarian cancer cells 
(PMID:15700312) 
PSMC1   
proteasome 
(prosome, macropain) 
26S subunit, ATPase, 
1 
  cytoplasm   
ATPase with a chaperone-like 
activity 
  
autoantigen in monoclonal gammopathy 
of undetermined significance (MGUS), the 
premalignant stage of multiple myeloma 
(PMID:19587378) 
PTGFR   
prostaglandin F 
receptor (FP) 
  
plasma 
membrane 
  
a receptor for prostaglandin F2-
alpha (PGF2-alpha), which is 
known to be a potent luteolytic 
agent 
  
higher expression in endometrial 
adenocarcinomas (PMID:14764825) 
PTPRA 
 
protein tyrosine 
phosphatase, receptor 
type, A 
 
plasma 
membrane  
dephosphorylate and activate Src 
family tyrosine kinases  
- higher copy number and expression in 
gastric cancer (PMID:20187983, 
16338072) 
            
 
  
- shorter isoform induces cellular 
transformation (PMID:20545765) 
RAB7L1   
RAB7, member RAS 
oncogene family-like 1 
  membrane   small GTPase     
SCYL3   
SCY1-like 3 (S. 
cerevisiae) 
  
cytoplasm, 
Golgi 
  cytoskeletal adaptor protein     
 
  
  
 
 
 
Figure 1.  Schematic of Serum Screening Strategy.  Ovarian cancer sera were sequentially tested on custom 
microarrays as shown. Initial screening was performed using arrays expressing 5,177 unique full length cDNAs 
and case/control sera (Cohort 1).  Secondary screening was performed using arrays expressing 741 unique full 
length cDNAs (Cohort 2), and 12 antigens were re-tested by Luminex ELISA.  The specificity of the top 7 
antigens were determined using sera from non-serous cases/controls (Cohort 3) and serous cases with low 
CA125 levels. 
 
 
• 34 serous cases/30 controls
– Goal: Eliminate antigens
Stage 1:
Pre-Screen
5,177 Ag’s
Stage 2:
Training set
741 Ag’s
• 60 serous cases/60 controls
– Goal: Select top antigens
Stage 3:
Specificity
7 Ag’s
• 30 non-serous cases/30 controls
• 20 Low CA 125 cases/15 controls
- Goal: Determine specificity
Retest 12 top antigens by Luminex
